Literature DB >> 23920371

Three-dimensional configuration of subretinal fluid in central serous chorioretinopathy.

Soh-Eun Ahn1, Jaeryung Oh, Jong-Hyun Oh, In Kyung Oh, Seong-Woo Kim, Kuhl Huh.   

Abstract

PURPOSE: The purpose of this study was to characterize the 3-dimensional (3D) configuration of subretinal fluid (SRF) in idiopathic central serous chorioretinopathy (CSC) using spectral-domain optical coherence tomography (SDOCT).
METHODS: The OCT images of patients with CSC were reviewed retrospectively. The 3D configurations of SRF were assessed using a modified segmentation algorithm of SDOCT. The differences of the configurations between acute and chronic CSC were compared. For the patients with acute CSC, we investigated a possible relationship between early change in 3D configuration and disease prognosis.
RESULTS: We included 69 eyes of 68 patients in this study. The mean volume, the greatest basal diameter (GBD), and the area of SRF were not different between acute and chronic CSC. The mean peak height (PH) of SRF and the ratio of PH to GBD in acute CSC (298.13 ± 92.67 μm, 9.44 ± 2.57%) were significantly greater than those in chronic CSC (192.97 ± 71.05 μm, 5.97 ± 1.90%; P < 0.001, P < 0.001, respectively). In patients with acute CSC, the early changing pattern of 3D configurations was significantly different according to the SRF prognosis (P = 0.003). In situ decrease of SRF was observed in 94.7% of the spontaneously resolving group. However, downward elongation of SRF was observed more frequently in the persistent group (58.3%) than in the spontaneously resolving group (6.3%).
CONCLUSIONS: The 3D configurations of SRF were different between acute and chronic CSC. In patients with acute onset, the early change of 3D configuration was different and varied according to the SRF prognosis.

Entities:  

Keywords:  central serous chorioretinopathy; optical coherence tomography; subretinal fluid; three-dimensional configuration

Mesh:

Year:  2013        PMID: 23920371     DOI: 10.1167/iovs.13-12279

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Retinal sensitivity assessed by microperimetry and corresponding retinal structure and thickness in resolved central serous chorioretinopathy.

Authors:  H W Chung; C M Yun; J T Kim; S-W Kim; J Oh; K Huh
Journal:  Eye (Lond)       Date:  2014-08-01       Impact factor: 3.775

2.  Correlation of subretinal fluid volume with choroidal thickness and macular volume in acute central serous chorioretinopathy.

Authors:  A Goktas
Journal:  Eye (Lond)       Date:  2014-09-19       Impact factor: 3.775

3.  Central serous chorioretinopathy fundus autofluorescence comparison with two different confocal scanning laser ophthalmoscopes.

Authors:  Ki Tae Nam; Cheol Min Yun; Jee Taek Kim; Kyung-Sook Yang; Hyun Joo Kim; Seong-Woo Kim; Jaeryung Oh; Kuhl Huh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-18       Impact factor: 3.117

4.  Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.

Authors:  G A Kim; T H Rim; S C Lee; S H Byeon; H J Koh; S S Kim; C S Lee
Journal:  Eye (Lond)       Date:  2015-05-08       Impact factor: 3.775

5.  The association between visual function and retinal structure in chronic central serous chorioretinopathy.

Authors:  Aya Sugiura; Ryosuke Fujino; Nobuko Takemiya; Kimiko Shimizu; Masato Matsuura; Hiroshi Murata; Tatsuya Inoue; Ryo Obata; Ryo Asaoka
Journal:  Sci Rep       Date:  2017-11-24       Impact factor: 4.379

6.  Association between visual function and the integrity of residual ellipsoid zone in resolved central serous chorioretinopathy.

Authors:  Asahi Fujita; Yurika Aoyama; Saori Tsuneyoshi; Aya Sugiura; Keiko Azuma; Kimiko Asano-Shimizu; Hirotsugu Soga; Yohei Hashimoto; Ryo Asaoka; Tatsuya Inoue; Ryo Obata
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

Review 7.  Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy.

Authors:  Gregor S Reiter; Ursula Schmidt-Erfurth
Journal:  Ther Adv Ophthalmol       Date:  2022-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.